A cohort study of enfuvirtide immunological and virological efficacy in clinical practice

Journal of Medical Virology

Volumn 78, Issue 10, 2006, Pages 1312-1317

  Bienvenu, Boris ^a,b   Krivine, Anne ^b   Rollot, Florence ^b   Pietri, Marie Pierre ^b   Lebault, Valérie ^b   Meritet, Jean François ^b   Guerin, Corinne ^b   Spiridon, Gabriela ^b   Salmon, Dominique ^a,b   Guillevin, Loïc ^a,b   Lebon, Pierre ^a,b   Launay, Odile ^a,b  

^a UNIVERSITÉ PARIS DESCARTES   (France)

^b Institut Cochin   (France)

Author keywords

Dynamic of resistance mutations to enfuvirtide; gp41; HIV 1 infection; HR1; HR2; T 20; Treatment experienced patients

Indexed keywords

ALANINE; AMINO ACID; ANTIRETROVIRUS AGENT; ENFUVIRTIDE; GLYCOPROTEIN GP 41; PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR; VALINE; VIRUS RNA;

ADULT; AGED; ARTICLE; CD4 LYMPHOCYTE COUNT; CLINICAL ARTICLE; COHORT ANALYSIS; DRUG EFFICACY; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INJECTION SITE REACTION; MALE; RETROSPECTIVE STUDY; VIRUS LOAD; VIRUS MUTATION; VIRUS REPLICATION;

ADULT; AGED; CD4 LYMPHOCYTE COUNT; COHORT STUDIES; DRUG RESISTANCE, VIRAL; FEMALE; HIV ENVELOPE PROTEIN GP41; HIV FUSION INHIBITORS; HIV INFECTIONS; HIV-1; HOSPITALS, TEACHING; HUMANS; MALE; MIDDLE AGED; MUTATION; PEPTIDE FRAGMENTS; PROTEIN STRUCTURE, TERTIARY; RETROSPECTIVE STUDIES; RNA, VIRAL; SALVAGE THERAPY; TREATMENT OUTCOME; VIRAL LOAD;

HUMAN IMMUNODEFICIENCY VIRUS 1;

EID: 33748641708     PISSN: 01466615     EISSN: 10969071     Source Type: Journal    
DOI: 10.1002/jmv.20700     Document Type: Article

References (22)

1. Carmona R, Perez-Alvarez L, Munoz M, Casado G, Delgado E, Sierra M, Thomson M, Vega Y, Vazquez de Parga E, Contreras G, Medrano L, Najera R. 2005. Natural resistance-associated mutations to Enfuvirtide (T20) and polymorphisms in the gp41 region of different HIV-1 genetic forms from T20 naive patients. J Clin Virol 32:248-253.
2. Clotet B, Raffi F, Cooper D, Delfraissy JF, Lazzarin A, Moyle G, Rockstroh J, Soriano V, Schapiro J. 2004. Clinical management of treatment-experienced, HIV-infected patients with the fusion inhibitor enfuvirtide: Consensus recommendations. Aids 18:1137-1146.
3. DeGruttola V, Dix L, D'Aquila R, Holder D, Phillips A, Ait-Khaled M, Baxter J, Clevenbergh P, Hammer S, Harrigan R, Katzenstein D, Lanier R, Miller M, Para M, Yerly S, Zolopa A, Murray J, Patick A, Miller V, Castillo S, Pedneault L, Mellors J. 2000. The relation between baseline HIV drug resistance and response to antiretroviral therapy: Re-analysis of retrospective and prospective studies using a standardized data analysis plan. Antivir Ther 5:41-48.
4. Greenberg ML, Cammack N. 2004. Resistance to enfuvirtide, the first HIV fusion inhibitor. J Antimicrob Chemother 54:333-340.
5. Hanna SL, Yang C, Owen SM, Lal RB. 2002. Variability of critical epitopes within HIV-1 heptad repeat domains for selected entry inhibitors in HIV-infected populations worldwide [corrected]. Aids 16:1603-1608.
6. Kilby JM, Hopkins S, Venetta TM, DiMassimo B, Cloud GA, Lee JY, Alldredge L, Hunter E, Lambert D, Bolognesi D, Matthews T, Johnson MR, Nowak MA, Shaw GM, Saag MS. 1998. Potent suppression of HIV-1 replication in humans by T-20, a peptide inhibitor of gp41-mediated virus entry. Nat Med 4:1302-1307.
7. Lalezari JP, Henry K, O'Hearn M, Montaner JS, Piliero PJ, Trottier B, Walmsley S, Cohen C, Kuritzkes DR, Eron JJ, Jr., Chung J, DeMasi R, Donatacci L, Drobnes C, Delehanty J, Salgo M. 2003. Enfuvirtide, an HIV-1 fusion inhibitor, for drug-resistant HIV infection in North and South America. N Engl J Med 348:2175-2185.
8. Lazzarin A, Clotet B, Cooper D, Reynes J, Arasteh K, Nelson M, Katlama C, Stellbrink HJ, Delfraissy JF, Lange J, Huson L, DeMasi R, Wat C, Delehanty J, Drobnes C, Salgo M. 2003. Efficacy of enfuvirtide in patients infected with drug-resistant HIV-1 in Europe and Australia. N Engl J Med 348:2186-2195.
9. Lu J, Sista P, Giguel F, Greenberg M, Kuritzkes DR. 2004. Relative replicative fitness of human immunodeficiency virus type 1 mutants resistant to enfuvirtide (T-20). J Virol 78:4628-4637.
10. Marcelin AG, Reynes J, Yerly S, Ktorza N, Segondy M, Piot JC, Delfraissy JF, Kaiser L, Perrin L, Katlama C, Calvez V. 2004. Characterization of genotypic determinants in HR-1 and HR-2 gp41 domains in individuals with persistent HIV viraemia under T-20. Aids 18:1340-1342.
11. Melby T, Sista P, Demasi R, Kirkland T, Roberts N, Salgo M, Heilek-Snyder G, Cammack N, Matthews TJ, Greenberg ML. 2006. Characterization of envelope glycoprotein gp41 genotype and phenotypic susceptibility to enfuvirtide at baseline and on treatment in the phase III clinical trials TORO-1 and TORO-2. AIDS Res Hum Retroviruses 22:375-385.
12. Menzo S, Castagna A, Monachetti A, Hasson H, Danise A, Carini E, Bagnarelli P, Lazzarin A, Clementi M. 2004. Genotype and phenotype patterns of human immunodeficiency virus type 1 resistance to enfuvirtide during long-term treatment. Antimicrob Agents Chemother 48:3253-3259.
13. Mink M, Mosier SM, Janumpalli S, Davison D, Jin L, Melby T, Sista P, Erickson J, Lambert D, Stanfield-Oakley SA, Salgo M, Cammack N, Matthews T, Greenberg ML. 2005. Impact of human immunodeficiency virus type 1 gp41 amino acid substitutions selected during enfuvirtide treatment on gp41 binding and antiviral potency of enfuvirtide in vitro. J Virol 79:12447-12454.
14. Nelson M, Arasteh K, Clotet B, Cooper DA, Henry K, Katlama C, Lalezari JP, Lazzarin A, Montaner JS, O'Hearn M, Piliero PJ, Reynes J, Trottier B, Walmsley SL, Cohen C, Eron JJ, Jr., Kuritzkes DR, Lange J, Stellbrink HJ, Delfraissy JF, Buss NE, Donatacci L, Wat C, Smiley L, Wilkinson M, Valentine A, Guimaraes D, Demasi R, Chung J, Salgo MP. 2005. Durable efficacy of enfuvirtide over 48 weeks in heavily treatment-experienced HIV-1-infected patients in the T-20 versus optimized background regimen only 1 and 2 clinical trials. J Acquir Immune Defic Syndr 40:404-412.
15. Perez-Alvarez L, Carmona R, Ocampo A, Asorey A, Miralles C, Perez de Castro S, Pinilla M, Contreras G, Taboada JA, Najera R. 2006. Long-term monitoring of genotypic and phenotypic resistance to T20 in treated patients infected with HIV-1. J Med Virol 78:141-147.
16. Poveda E, Rodes B, Lebel-Binay S, Faudon JL, Jimenez V, Soriano V. 2005. Dynamics of enfuvirtide resistance in HIV-infected patients during and after long-term enfuvirtide salvage therapy. J Clin Virol 34:295-301.
17. Raffi F, Katlama C, Saag M, Wilkinson M, Chung J, Smiley L, Salgo M. 2006. Week-12 response to therapy as a predictor of week 24, 48, and 96 outcome in patients receiving the HIV fusion inhibitor enfuvirtide in the T-20 versus Optimized Regimen Only (TORO) trials. Clin Infect Dis 42:870-877.
18. Rimsky LT, Shugars DC, Matthews TJ. 1998. Determinants of human immunodeficiency virus type 1 resistance to gp41-derived inhibitory peptides. J Virol 72:986-993.
19. Sista PR, Melby T, Davison D, Jin L, Mosier S, Mink M, Nelson EL, DeMasi R, Cammack N, Salgo MP, Matthews TJ, Greenberg ML. 2004. Characterization of determinants of genotypic and phenotypic resistance to enfuvirtide in baseline and on-treatmeht HIV-1 isolates. Aids 18:1787-1794.
20. Trottier B, Walmsley S, Reynes J, Piliero P, O'Hearn M, Nelson M, Montaner J, Lazzarin A, Lalezari J, Katlama C, Henry K, Cooper D, Clotet B, Arasteh K, Delfraissy JF, Stellbrink HJ, Lange J, Kuritzkes D, Eron JJ, Jr., Cohen C, Kinchelow T, Bertasso A, Labriola-Tompkins E, Shikhman A, Atkins B, Bourdeau L, Natale C, Hughes F, Chung J, Guimaraes D, Drobnes C, Bader-Weder S, Demasi R, Smiley L, Salgo MP. 2005. Safety of enfuvirtide in combination with an optimized background of antiretrovirals in treatment-experienced HIV-1-infected adults over 48 weeks. J Acquir Immune Defic Syndr 40:413-421.
21. Wei X, Decker JM, Liu H, Zhang Z, Arani RB, Kilby JM, Saag MS, Wu X, Shaw GM, Kappes JC. 2002. Emergence of resistant human immunodeficiency virus type 1 in patients receiving fusion inhibitor (T-20) monotherapy. Antimicrob Agents Chemother 46:1896-1905.
22. Xu L, Pozniak A, Wildfire A, Stanfield-Oakley SA, Mosier SM, Ratcliffe D, Workman J, Joall A, Myers R, Smit E, Cane PA, Greenberg ML, Pillay D. 2005. Emergence and evolution of enfuvirtide resistance following long-term therapy involves heptad repeat 2 mutations within gp41. Antimicrob Agents Chemother 49:1113-1119.